NEW DELHI: Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities.
Three vaccine candidates - Serum Institute-Oxford s Covishield, Bharat Biotech s Covaxin and Pfizer vaccine are in the fray for emergency use authorization. The Central Drugs Standard Control Organisation (CDSCO) has sought additional data from the Serum Institute as well as Bharat Biotech to get approval.
India crosses 1 Cr Covid cases
Sat, Dec 19 2020 10:42:47 AM
New Delhi, Dec 19 (IANS): In a major development, India on Saturday recorded 25,152 new coronavirus cases and 347 deaths, taking the total number of infected people since January past the one crore-mark, according to the Ministry of Health and Family Welfare s data.
The country crossed the grim milestone almost eleven months after the first case was reported on January 30 in the Thrissur district of Kerala. Since then, the country has recorded 10,004,599 coronavirus cases and 14,51,36 deaths.
The number of infections had crossed the 10 lakh-mark on July 17; 20 lakh on August 7; 30 lakh on August 23; 40 lakh on September 5; 50 lakh on September 16; 60 lakh on September 28; 70 lakh on October 11; 80 lakh on October 29; and 90 lakh on November 20.
COVID vaccine distribution requires funding of Rs 80,000 crore, says Serum Institute of India
Serum Institute-Oxford s Covishield, Bharat Biotech s Covaxin and Pfizer vaccine are in the fray for emergency use authorization. (Image: Reuters)
Updated: Dec 19, 2020, 05:31 PM IST
Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities.
Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year. The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities. Three vaccine candidates - Serum Institute-Oxford s Covishield, Bharat Biotech s Covaxin and Pfizer vaccine are in the fray for emergency use authorization. The Central Drugs Standard Control Organisation (CDSCO) has sought additional data from the Serum Institute as well as Bharat Biotech to get approval.